Cato Capital LLC v. Hemispherx Biopharma Inc.

625 F. App'x 108
CourtCourt of Appeals for the Third Circuit
DecidedAugust 21, 2015
Docket14-4244
StatusUnpublished

This text of 625 F. App'x 108 (Cato Capital LLC v. Hemispherx Biopharma Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cato Capital LLC v. Hemispherx Biopharma Inc., 625 F. App'x 108 (3d Cir. 2015).

Opinion

OPINION *

GREENAWAY, JR., Circuit Judge.

Plaintiff-Appellant Cato Capital, 'LLC (“Cato”) appeals from the final judgment entered by the District Court in favor of Defendant-Appellee Hemispherx Biophar-ma, Inc. (“Hemispherx”) on Cato’s breach of contract claim. Cato, an investment bank, sued Hemispherx, a biopharmaceutical company and former client, to recover a placement fee after several companies invested millions of dollars in Hemis-pherx — notwithstanding the fact that: (1) Cato did not facilitate these investments, and (2) these transactions closed after Cato’s engagement with Hemispherx had expired. After a bench trial, the District Court held: (1) that Cato had not satisfied a condition precedent to payment under the contract, and (2) that Cato was not entitled to payment under the contract because Cato did not cause the investments. See Cato Capital LLC v. Hemis-pherx Biopharma, Inc., 70 F.Supp.3d 607 (D.Del.2014). We agree that Cato did not satisfy a condition precedent to payment and will affirm the District Court. 1

I. Background

A. Factual History

1. The Beginning of the Engagement

In late 2008, Cato was introduced to Hemispherx by Hemispherx’s advisor, The Sage Group, Inc. (“Sage”). Hemispherx and Cato entered into a non-exclusive contract (“the-Agreement”) whereby Cato would serve as Hemispherx’s “financial adviser and placement agent, in connection with facilitating debt and equity financings for [Hemispherx]” for a term beginning November 24, 2008 and ending March 24, 2009. JA 0094-95. The Agreement also provided for an additional eight-month period after the expiration of the term of the engagement (the “Tail Period”), during which time, if Hemispherx closed a transaction with any investor introduced to Hemispherx by Cato (a “Tail Period transaction”), Hemispherx would be obligated to pay Cato a “Placement Fee” under certain conditions, JA 0095.

■Specifically, Paragraphs 2(b) and 2(c) of the Agreement required Cato to provide to Hemispherx two separate lists of potential investors (the “Cato Prospects”). They provided in relevant part:

(b) Payment of Fees: All applicable fees shall be payable ... with respect to any Transaction completed with any Cato Prospect during ... (ii) the eight month period (the “Tail Period”) following- the term of this Agreement. At the end of the term of this Agreement, Cato shall designate in writing to the Company *110 all Cato Prospects. Cato will brily be entitled to Placement Fees for Transactions during the Tail Period completed with any of the listed Cato Prospects or their affiliates.
* * *
(c) ____ Following the execution of this Agreement, Cato will immediately provide Company with a list of Cato Prospects which will be immediately reviewed by Company. and once agreed, Cato Prospects will be attached to this agreement as appendix A.

Id. (emphasis added).

The day the Agreement was executed, Cato submitted a list of Cato Prospects (the “Paragraph 2(c) list”) for approval. Hemispherx approved the list and appended it to the Agreement. Days later, Cato sought and received approval for several additional prospects. The Cato Prospects included Hudson Bay Capital Management LP (“Hudson Bay”), Iroquois Capital (“Iroquois”), and Cranshire -Capital LP (“Cranshire”).

Within the next two weeks, Cato sent Iroquois, Cranshire, and Hudson Bay an email outlining a proposed transaction. Cato, however, failed to secure any suitable offers and had no further contact with these prospects.

2. Updated Prospects and the End of the Term

On January 5, 2009, Cato submitted the names of additional investors for Hemis-pherx’s approval. Hemispherx,- through ■ Sage, 2 approved the investors the next day and requested a “full list, updated,” of all Cato Prospects. Cato sent the requested list on January 7, 2009. The list included, inter alia, Iroquois, Hudson Bay, and Cranshire.

On March 24, 2009, the term of the Agreement ended with Cato having failed to secure any funding for Hemispherx. Cato did not submit a Paragraph 2(b) list of Cato Prospects at that time.

3. The Tail Period

In - late April, Rodman and Renshaw Capital Group (“Rodman”) contacted Hem-: ispherx because of the increased market interest in companies — like Hemispherx— with products capable of treating influenza. Rodman believed that Hemispherx could raise capital through an equity offering in this climate, and the two executed an engagement letter in early May. Soon thereafter, Hudson Bay, Cranshire, and Iroquois collectively invested $23.5 million in Hemispherx with Rodman acting as facilitator.

On May 22, 2009, Cato sent Hemispherx a demand letter seeking fees for the transactions that Hemispherx had concluded with Hudson Bay, Iroquois, and Cranshire. Hemispherx refused to pay Cato because it had not submitted a Paragraph 2(b) list and had not facilitated these transactions.

B. Procedural History

Cato filed suit in the District Court against Hemispherx alleging, inter alia, breach of contract, • and against The Sage Group alleging fraud and intentional interference with a contractual relationship. After a three-day bench trial, the District Court ruled against Cato on all counts. Cato timely appealed only the breach of contract of claim, arguing: (1) that it substantially complied with Paragraph 2(b)’s requirement by sending the updated list of prospects in January 2009, and (2) that the Agreement entitles Cato to payment for any transaction consummated with a Cato Prospect during the Tail Period, regard *111 less of whether Cato caused the transaction.

II. Analysis 3

We review a district court’s findings of fact following a bench trial under the clearly erroneous standard and exercise plenary review over its conclusions of law. Gordon v. Lewistown Hosp., 423 F.3d 184, 201 (3d Cir.2005). Under Delaware law, 4 contract interpretation is a question of law. Rhone-Poulenc Basic Chems. Co. v. Am. Motorists Ins. Co., 616 A.2d 1192, 1195 (Del.1992). Generally, whether a party can satisfy the doctrine of substantial compliance is a question of fact. See Standard Accident Ins. Co. v. Ponsell’s Drug Stores, Inc., 202 A.2d 271, 275 (Del.1964).

A court interpreting a contract must effectuate the parties’ intent. See Loril-lard Tobacco Co. v. Am. Legacy Found.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
Standard Acc. Ins. Co. v. Ponsell's Drug Stores, Inc.
202 A.2d 271 (Supreme Court of Delaware, 1964)
Rhone-Poulenc Basic Chemicals Co. v. American Motorists Insurance Co.
616 A.2d 1192 (Supreme Court of Delaware, 1992)
Northwestern National Insurance v. Esmark, Inc.
672 A.2d 41 (Supreme Court of Delaware, 1996)
NAMA Holdings, LLC v. World Market Center Venture, LLC
948 A.2d 411 (Court of Chancery of Delaware, 2007)
Randy v. Progressive Northern Insurance Co.
785 A.2d 281 (Supreme Court of Delaware, 2001)
AES Puerto Rico, L.P. v. ALSTOM Power, Inc.
429 F. Supp. 2d 713 (D. Delaware, 2006)
Cato Capital LLC v. Hemispherx Biopharma, Inc.
70 F. Supp. 3d 607 (D. Delaware, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
625 F. App'x 108, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cato-capital-llc-v-hemispherx-biopharma-inc-ca3-2015.